Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Trial Profile

Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 21 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary) ; Pembrolizumab (Primary) ; Rintatolimod (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2023 According to a AIM ImmunoTech media release, Principal investigator and first author Shipra Gandhi of the Department of Medicine at Roswell Park, led the study under the scientific leadership of Pawel Kalinski.
    • 14 Nov 2023 According to a AIM ImmunoTech media release, results from this trial were published in the Journal for ImmunoTherapy of Cancer.
    • 17 Jul 2023 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top